- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer
This study is looking at new ways to treat advanced bowel cancer (colorectal cancer that has spread). It combines existing treatments with new drugs to see if they work better together. The aim is to find safer and more effective options for patients.
For: Metastatic colorectal cancerFrance · Italy · Spain - RecruitingPHASE2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
This study looks at new ways to treat bladder cancer that has spread or can't be removed with surgery. It's testing a drug called sacituzumab govitecan, sometimes on its own, and sometimes with other new treatments, to see if they are safe and effective.
For: Metastatic Urothelial CancerUnited States · France · Germany - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
For: Non-small Cell Lung CancerUnited States · Argentina · Austria - Active not recruitingPHASE3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This study is testing a new combination of medicines with chemotherapy for some upper gut cancers that have spread and can't be removed by surgery. It aims to see if the new combination works better than current treatments.
For: Advanced Upper Gastrointestinal Tract AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE2
Study With Various Immunotherapy Treatments in Participants With Lung Cancer
This study is looking at new combinations of medicines for advanced lung cancer. It aims to see how well different immunotherapy treatments work together and how safe they are for patients. The goal is to find better ways to treat this type of lung cancer.
For: Advanced Non-Small Cell Lung CancerUnited States · Australia · France - Active not recruitingPHASE1
Study of GS-4528 in Adults With Solid Tumors
This study is testing a new drug, GS-4528, on its own or with another drug, Zimberelimab, for adults with solid cancers. Researchers want to find out if it's safe, what dose works best, and if people can tolerate it.
For: Solid TumorUnited States · Canada · South Korea - Active not recruitingPHASE2
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
This study is testing new combinations of treatments for head and neck cancer that has come back or spread. It compares two new drugs plus chemotherapy against one new drug plus chemotherapy. The aim is to find safer and more effective ways to treat this type of cancer.
For: Head and Neck Squamous Cell CarcinomaUnited States · Australia · China - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Novel Combination Therapies in Participants With Previously Untreated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status
This study is looking for new treatment combinations for head and neck cancer that has come back or spread. It's a Phase 2 trial, meaning researchers want to see how well these new drug combinations work and if they are safe.
For: Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaItaly · Spain · France - AuthorisedTherapeutic exploratory (Phase II)
A multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer (NeoTRACE) [without IMPD-Q]
This study is for people with a type of lung cancer that can be removed with surgery. It looks at new treatments given before and after surgery to see if they can help shrink the cancer and stop it from coming back.
For: non-small cell lung cancerGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma with progression during or after peri-operative chemotherapy.
This study looks at new treatments for advanced stomach or gastro-oesophageal junction cancer that has grown despite earlier chemotherapy. We're testing if adding two new drugs, domvanalimab and zimberelimab, to standard chemotherapy (FOLFIRI) helps patients live longer without their cancer getting worse.
For: stomach cancer · Esophage · gastro-oesophageal junction adenocarcinomaFrance - AuthorisedTherapeutic exploratory (Phase II)
Bladder Preservation with Sacituzumab Govitecan + Zimberelimab for MuscleInvasive Bladder cancer in cisplatin-unfit and unwilling for cystectomy patients: phase II trial (preSAVE trial)
This study looks at new treatments (Zimberelimab and Trodelvy) for muscle-invasive bladder cancer in people who can't have surgery or choose not to. We want to see how well these drugs can help control the cancer and avoid surgery.
For: Muscle-Invasive Bladder cancerItaly - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)
This study is testing new drug combinations for advanced triple-negative breast cancer that has a specific marker called PD-L1. It aims to see if they are safe and help shrink tumours.
For: PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCERSpain